游客在兴文县苗医体验馆体验按摩。 王磊摄 在宜宾市兴文县，民族医药产业正蓬勃发展，成为当地经济增长和民族文化传播的新引擎。兴文县是四 川省苗族人口最多的县，这里山清水秀，气候适宜，拥有丰富的中苗药材资源。据第四次全国中药资源 普查，兴文县发现野生药用植物1000余种，其中重楼、天麻等道地药材久负盛名。 据了解，苗医药在兴文县传承千年，当地苗族群众很早就掌握了用草药治疗疾病的技艺，积累了丰富的 经验。为展示兴文县苗医药丰富的资源和深厚的文化底蕴，2021年11月，兴文县苗医体验馆投入使 用。"游客对民族医药抱有浓厚的兴趣。自开馆以来，已有数万名观众前来打卡。"兴文县苗医体验馆馆 长钟艳介绍称，馆内展示的300余种苗药，生动展现了民族医药的悠久历史和独特文化。群众可以在馆 内体验把脉问诊、药膳养生、看图识百草、亲手制香囊等"沉浸式"活动，还能在康养体验区享受休闲养 生、亚健康调理、理疗康养等多种服务。 龙塘村淫羊藿的种植，是当前四川推动民族医药发展的缩影。四川民族地区有2000多种药材资源，药材 蕴藏量超过25万吨，盛产多种高原名贵药材和道地药材，素有"天然药库"之称。近年来，四川坚持以铸 牢中华民族共同体意识为 ...

雅本化学股份有限公司投资者关系活动记录表 证券代码：300261 证券简称：雅本化学 编号：20250613 | 投资者关系活动 | ☑特定对象调研 □分析师会议 | | | --- | --- | --- | | 类别 | □媒体采访 □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 | 国联民生证券 赵嘉卉、吴君怡 | | | 人员姓名 | 华安证券 刘天其 | | | | 班培琪 建信保险资管 | | | 时间 | 2025 年 6 月 日 (周五) 下午 14:00~15:00 | 13 | | 地点 | 公司会议室 | | | 上市公司接待人 | 王一川 董秘、副总经理 | | | 员姓名 | 证券事务代表 朱佩芳 | | | 投资者关系 | 1、请介绍一下公司氯虫苯甲酰胺中间体业务及销售情况？ | | | | 子公司南通雅本化学有限公司具备 吨/年的氯虫苯甲酰 2000 | | | | 胺中间体 K 酸的产能，采用 CDMO 业务模式，可根据客户订单 | | | | 需求提供定制化生产及 ...

Financial Data - In May, the social financing increment was 2.29 trillion yuan, an increase of 224.7 billion yuan year-on-year; new RMB loans were nearly 620 billion yuan [2] - As of the end of May, the broad money supply (M2) grew by 7.9% year-on-year, a slight decrease of 0.1 percentage points from the previous month, but up 0.9 percentage points from the same period last year [2] Regulatory Updates - The China Securities Regulatory Commission (CSRC) issued the "Procedures for the Management of Program Trading in the Futures Market (Trial)," which mandates regular checks on program traders' reported information, focusing on high-frequency traders [2] - The Shanghai Stock Exchange announced that CATL's H-shares will be included in the southbound trading list of the Hong Kong Stock Connect, effective from the next trading day [2] Industry Oversight - The State Administration for Market Regulation emphasized increased antitrust enforcement in the pharmaceutical sector to protect public health and ensure affordable medication [3] - A joint notice from 14 ministries outlined key points for correcting misconduct in the pharmaceutical sales and medical services sectors, focusing on enhancing regulatory responsibilities and addressing corruption [4] Market Measures - The Shanghai International Energy Exchange issued a notice urging market participants to implement risk control measures amid volatile international conditions [5] - The Beijing Stock Exchange extended the exemption from transaction fees for bond trading until December 31, 2026 [7] Company News - Huayang New Materials announced it is not involved in the rare earth permanent magnet sector [7] - China National Petroleum Engineering signed a contract worth 1.601 billion USD for the Atawi GPP project [7] - Cheng Tian Wei Ye highlighted risks related to the commercialization of new technologies and products [7] - Honghui Fruits and Vegetables will have its controlling shareholder change to Shenze Ruitai and will resume trading on June 16 [7] - Zhuhai International Electric Power signed two strategic cooperation agreements for solar projects in Zambia [7] - Pan-Asia Micro-Optics plans to establish a subsidiary in Changzhou to enhance its medical application layout [8] - Dongshan Precision intends to invest up to 5.935 billion yuan in Solstice Optoelectronics to expand its optical communication layout [8]

Core Viewpoint - The joint announcement by 14 ministries aims to strengthen the governance of the pharmaceutical and medical service sectors, focusing on preventing corruption and ensuring compliance within the industry [1][2][3]. Group 1: Governance and Compliance - Continuous efforts are required to consolidate the achievements in the governance of the pharmaceutical procurement and sales sector, with a focus on preventing the resurgence of corruption [1]. - The establishment of a credit system in the pharmaceutical distribution industry is emphasized, along with the implementation of a "blacklist" system for bribers and corrupt entities [2]. - The announcement encourages pharmaceutical companies to enhance compliance management by referring to guidelines aimed at preventing commercial bribery [1][2]. Group 2: Regulatory Measures - The document outlines the need for a comprehensive audit and supervision mechanism that covers the entire process from raw material procurement to drug production and distribution [1]. - Specific measures to regulate internet medical practices are highlighted, including the need for consistent qualifications and activities between online and physical medical institutions [2]. - A multi-departmental collaborative mechanism is proposed to address illegal activities in the medical internet space, such as fraudulent advertising and unauthorized marketing practices [2]. Group 3: Ethical Standards and Patient Protection - The responsibility of medical institutions in managing medical ethics is reinforced, with a zero-tolerance policy for violations that harm public interests and patient rights [3]. - The safety of medical insurance funds is prioritized, with strict measures against fraud and misuse of funds, ensuring accountability at the individual level [3]. - The announcement calls for the optimization of centralized procurement platforms for drugs and high-value medical consumables to enhance quality and efficiency [3].

证券研究报告 | 公司深度报告 2025 年 06 月 13 日 太龙药业（600222.SH） 国资赋能+集采放量，中药 CRO 打开第二曲线 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,070 | 1,941 | 2,132 | 2,348 | 2,583 | | 增长率 yoy（%） | 5.6 | -6.2 | 9.8 | 10.1 | 10.0 | | 归母净利润（百万元） | 44 | 51 | 61 | 85 | 116 | | 增长率 yoy（%） | 160.3 | 16.0 | 21.5 | 38.4 | 36.5 | | ROE（%） | 2.8 | 3.3 | 3.9 | 5.0 | 6.4 | | EPS 最新摊薄（元） | 0.08 | 0.09 | 0.11 | 0.15 | 0.20 | | P/E（倍） | 80.9 | 69.7 | 57.4 | 41.5 | 30.4 | | P/B（倍） | 2.2 | 2.2 ...

Core Viewpoint - GuangYuYuan Chinese Herbal Medicine Co., Ltd. is preparing for its 2024 annual shareholders' meeting, focusing on maintaining shareholder rights and ensuring efficient proceedings [1][2][3]. Meeting Arrangements - The annual shareholders' meeting is scheduled for June 24, 2025, at 14:00 in Taiyuan, Shanxi [3]. - Shareholders must arrive 30 minutes early for registration and are limited to three minutes for speaking [2][3]. - Voting will occur both on-site and through internet platforms during specified time slots [3]. Agenda Items - The meeting will cover several key reports, including the 2024 annual work report from the board of directors, the supervisory board's report, financial statements, profit distribution plans, and independent directors' reports [3][4][5]. Board of Directors' Report - The board held six meetings during the reporting period, addressing various operational and financial matters, including accounting errors and annual reports [6][7]. - The company reported total assets of 2.276 billion and net assets of 1.570 billion as of December 31, 2024, with a revenue of 1.221 billion, a decrease of 4.87% year-on-year [13]. Operational Focus - The company emphasizes growth and operational efficiency, focusing on four core products and expanding its market presence through partnerships and new store openings [13][14]. - A cultural heritage strategy is in place to enhance brand influence, including collaborations with educational institutions and media [14][15]. Quality Assurance - The company is committed to high-quality production standards, implementing a comprehensive quality management system and collaborating with research institutions for innovation [15][16][20]. Governance and Compliance - The company is enhancing its governance structure, focusing on compliance and risk management, and has revised various internal regulations to ensure transparency and accountability [17][22][27]. Future Strategy - The company aims to strengthen its market position by leveraging its historical and cultural assets, enhancing brand visibility, and driving innovation through technology [19][21][22].

Group 1 - The State Administration for Market Regulation announced two antitrust enforcement cases in the pharmaceutical sector during a press conference on June 13, 2023 [1] - In the case involving the raw material drug Dexamethasone Sodium Phosphate, four companies collectively raised the price from 8,000 yuan per kilogram to 13,000 yuan, resulting in a total fine of 362 million yuan [1][2] - The companies involved in the price-fixing agreement included Tianjin Jiyuan Pharmaceutical Co., Zhejiang Xianju Pharmaceutical Co., Jiangsu Lianhuan Pharmaceutical Co., and Xi'an Guokang Ruijin Pharmaceutical Co. [1] Group 2 - The Tianjin Market Regulation Commission imposed administrative penalties, including a maximum fine of 5 million yuan on individual Guo, and confiscated illegal gains from the four companies, totaling 354 million yuan [2] - Each of the four companies was fined 8% of their previous year's sales for participating in the price-fixing agreement, and four responsible individuals were fined 600,000 yuan each [2] - In March 2023, authorities also penalized companies involved in a separate case regarding the injection of Neostigmine Methylsulfate, with total fines amounting to 223 million yuan [2]

Core Viewpoint - The company is preparing for its 2024 Annual General Meeting, focusing on governance, financial performance, and strategic initiatives for growth in the pharmaceutical automation sector. Group 1: Meeting Procedures and Governance - The meeting will take place on June 25, 2025, at 14:00 in Shanghai, combining on-site and online voting methods [6][12]. - Attendees must register and present identification to confirm their eligibility to participate [2][3]. - The meeting will include a series of agenda items, including the presentation of reports and voting on various proposals [6][7]. Group 2: Financial Performance - The company reported a net profit of 32,520,676.27 yuan for the year, a decrease of 45.80% compared to the previous year [11][24]. - The total assets of the company reached 146,601.12 million yuan, reflecting growth due to market expansion efforts [24]. - The company has decided not to distribute cash dividends for 2024, with retained earnings of 233,162,211.41 yuan to be reinvested for future growth [10][11]. Group 3: Industry Context and Company Strategy - The pharmaceutical automation industry is experiencing rapid growth driven by technological advancements and increasing healthcare demands [12][13]. - The company is positioned as a provider of comprehensive solutions in the pharmaceutical automation sector, focusing on product design, development, and after-sales service [13][14]. - Strategic initiatives include expanding into international markets, enhancing partnerships with leading retail pharmacies, and developing smart pharmacy solutions [14][25]. Group 4: Future Plans and Innovations - The company aims to enhance its R&D capabilities and expand its market presence, particularly in overseas markets [30][31]. - Plans include leveraging AI technology to improve healthcare services and developing innovative products tailored to market needs [31]. - The company is committed to maintaining strong investor relations and ensuring transparent communication regarding its strategic direction and financial performance [29][31].

金十数据6月13日讯，国家卫生健康委等14部门发布《关于印发2025年纠正医药购销领域和医疗服务中 不正之风工作要点》，其中提到，重点打击网络"医托"、违规发布医药广告，以及假借医学科普或会议 活动等"引流""带货"、伪造编造变造在职或离退休行业人员视频营销牟利等不法行为。紧盯定点医疗机 构、定点零售药店、职业骗保人，严厉打击欺诈骗保和整治违规使用医保基金行为，用好多部门联合惩 戒机制。 （央视新闻） 纠正医药购销领域和医疗服务中不正之风 14部委联合发文 ...

Core Viewpoint - The Sichuan Provincial Government has issued an opinion to support Chengdu in enhancing its core functions and accelerating high-quality development, aiming to establish it as a western economic center, technology innovation center, international exchange center, and a national advanced manufacturing base [1][2]. Group 1: Economic Development - The opinion outlines 15 specific measures to enhance Chengdu's economic growth, focusing on becoming a western economic center by expanding domestic demand and improving resource allocation capabilities [2]. - Chengdu is encouraged to develop into an international consumption center and to co-build a western financial center with Mianyang [2]. Group 2: Technological Innovation - The opinion emphasizes the need for Chengdu to strengthen its technological innovation capabilities, enhance the conversion of scientific achievements, and deepen reforms in the technology system [2][3]. - Chengdu will implement breakthrough actions in frontier technologies such as artificial intelligence, aerospace, biomanufacturing, and clean energy [2]. Group 3: International Exchange - To establish Chengdu as a western international exchange center, the opinion supports the development of a comprehensive international transportation hub and the strengthening of high-level open platforms [2]. - Specific initiatives include the construction of the Tianfu International Airport Phase II and the enhancement of the international flight network [2]. Group 4: Advanced Manufacturing - The opinion aims to support Chengdu in building a world-class advanced manufacturing cluster and nurturing emerging and future industries [3]. - Chengdu will establish new provincial development zones in the Tianfu New Area and the Eastern New Area, and develop a world-class high-tech industrial park [3].